Antisense oligonucleotides to inhibit expression of mutated and wild type genes for collagen
US5861502A · kind A · utility
12Cited by
1References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 1995 |
| Grant date | Jan 19, 1999 |
| Priority date | — |
| Expiry date | Jun 30, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/315
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to oligonucleotides that inhibit mutant COL1A1 and/or wild type COL1A1 gene expression. The present invention is further directed to methods of inhibiting mutant and/or wild type collagen gene expression using the disclosed inhibitory oligonucleotides. The oligonucleotides and methods of the present invention are useful for the treatment of mammals having diseases related to inappropriate mutant or wild type COL1A1 gene expression.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.